On June 7, 2024, Tharimmune, Inc., a Delaware-incorporated biotechnology company, announced the entry into an At the Market Offering Agreement with Rodman & Renshaw LLC. Under this agreement, Tharimmune may offer and sell its common stock through Rodman & Renshaw, acting as the sales agent. The sales will be conducted on an 'at the market' basis, meaning they could be made directly on the Nasdaq Stock Market or any other trading market for the company's common stock. Rodman & Renshaw is committed to using commercially reasonable efforts to sell the shares, following the company's instructions, including any imposed limits on price, time, or size of the sales. Tharimmune will pay a commission of 3.0% of the gross proceeds from the sales to Rodman...Show More

On June 7, 2024, Tharimmune, Inc., a Delaware-incorporated biotechnology company, announced the entry into an At the Market Offering Agreement with Rodman & Renshaw LLC. Under this agreement, Tharimmune may offer and sell its common stock through Rodman & Renshaw, acting as the sales agent. The sales will be conducted on an 'at the market' basis, meaning they could be made directly on the Nasdaq Stock Market or any other trading market for the company's common stock. Rodman & Renshaw is committed to using commercially reasonable efforts to sell the shares, following the company's instructions, including any imposed limits on price, time, or size of the sales. Tharimmune will pay a commission of 3.0% of the gross proceeds from the sales to Rodman & Renshaw. The agreement also includes customary indemnification and contribution rights, and Tharimmune is not obligated to sell any specific number of shares. The offering will continue until the agreement is terminated. The common stock is being offered pursuant to Tharimmune's effective shelf registration statement on Form S-3, declared effective by the SEC on March 24, 2023, and a prospectus supplement dated June 7, 2024. The legal opinion of Sheppard, Mullin, Richter & Hampton LLP regarding the common stock to be sold has been filed with the SEC as part of the agreement documentation.